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Abstract
Current single-locus-based analyses and candidate disease gene prediction
methodologies used in genome-wide association studies (GWAS) do not capi-
talize on the wealth of the underlying genetic data, nor functional data available
from molecular biology. Here, we analyzed GWAS data from the Wellcome
Trust Case Control Consortium (WTCCC) on coronary artery disease (CAD).
Gentrepid uses a multiple-locus-based approach, drawing on protein pathway-
or domain-based data to make predictions. Known disease genes may be used
as additional information (seeded method) or predictions can be based entirely
on GWAS single nucleotide polymorphisms (SNPs) (ab initio method). We
looked in detail at specific predictions made by Gentrepid for CAD and com-
pared these with known genetic data and the scientific literature. Gentrepid was
able to extract known disease genes from the candidate search space and predict
plausible novel disease genes from both known and novel WTCCC-implicated
loci. The disease gene candidates are consistent with known biological informa-
tion. The results demonstrate that this computational approach is feasible and a
valuable discovery tool for geneticists.
Introduction
Coronary artery disease (CAD) is the leading cause of
death and disability in the world (Lopez et al. 2006). Also
known as coronary heart disease, it involves narrowing of
the arteries and small blood vessels that supply blood and
oxygen to the heart, and is typically caused by the build-
up of plaque. Multiple risk factors have been identified
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for CAD that include family history, lipid levels, hyper-
tension, smoking, and diabetes (Swerdlow et al. 2012).
Heritability of CAD has been calculated to be between
40% and 50%, but only ~10% is explained by genetic
variations discovered to date (Peden and Farrall 2011).
The likely reason for the missing heritability is the com-
plex nature of the disease. Multiple genes and environ-
mental factors contribute to the phenotype, and causative
alleles may have small effects that are not detected by the
current methods used, such as genome-wide association
studies (GWAS). GWAS are designed to detect genetic
risk factors of complex diseases and quantitative traits
that are reasonably common in a population through the
assessment of correlations between genetic variants such
as single nucleotide polymorphisms (SNPs) and trait dif-
ferences. Unfortunately, rarer variants that are not directly
represented on the genotyping array, as well as common
variants with more modest effects, are harder to detect
because a highly stringent significance threshold is used
to correct for the number of false positives (Pearson and
Manolio 2008). SNPs that do not achieve genome-wide
statistical significance in these studies may still be of
importance.
Following detection of an association signal between a
SNP and the phenotype, the next step of identifying the
causal genetic basis is nontrivial for two reasons. First,
the SNP is most likely in linkage disequilibrium (LD)
with the true variant, as SNP chips contain only a selec-
tion of common variants and have incomplete coverage
of the genome. Second, even with knowledge of the true
variant, its functional significance may not be obvious as
the genetic architecture of the genome still remains
unclear. GWAS typically report the nearest neighboring
gene to the disease-associated SNP/locus, but this
assumption may not hold for all reported associations.
For instance, long range regulation and distal control ele-
ments suggest the disease gene may be near the significant
SNP but may not be the closest gene to it (Kikuta et al.
2007). Further to this, in work on simulated GWAS data,
it was found that synthetic associations can be created by
rarer alleles up to 2 Mbp from the true association signal
(Dickson et al. 2010), essentially lowering the resolution
of the association locus discovery. In recent work derived
from ENCODE, most variants from GWAS were shown
to be concentrated in regulatory regions of the DNA
(Maurano et al. 2012), with 40% enrichment of SNPs in
Deoxyribonuclease I (DNase I) hypersensitive sites
(DHS), and up to 76.6% in LD with a DHS. Around
40% of genes linked with a DHS are over 250 Kbp away
and not in LD with the SNP in the DHS.
In summary, the two main challenges in analyzing
GWAS data are the high false negative rate for genotype–
phenotype association, and low disease gene discovery
rate. With these shortcomings of GWAS in mind, we pre-
viously proposed a bioinformatic strategy to sift through
candidate genes near a larger number of SNPs by lower-
ing the significance threshold (Ballouz et al. 2011). The
increased number of genetic loci can be dealt with by
automated candidate gene prediction and prioritization
systems. There are currently many bioinformatic tools
available to predict and prioritize gene candidates which
have been reviewed elsewhere (Oti et al. 2011; Moreau
and Tranchevent 2012), each with varying underlying data
sources, inputs, algorithms, and ranking strategies. Several
tools have been adapted to allow the prioritization of
candidates from GWAS data (Holmans et al. 2009;
Raychaudhuri et al. 2009; Duncan et al. 2010; Wang et al.
2010). In this study, we used the candidate disease
gene prediction tool, Gentrepid, which uses two general
approaches: a systems biology approach, looking at path-
way data and protein–protein interaction (PPI) data; along
with a novel functional approach whereby protein domains
parsed in sequences are used to infer function. Although
previous pathway analyses of the Wellcome Trust Case
Control Consortium (WTCCC) (2007) study data has
shown that including biomolecular information identifies
numerous known and novel pathways (Torkamani et al.
2008; Elbers et al. 2009), no domain-based homology
analysis has yet been performed on this dataset.
Because Gentrepid looks at interactions and similarities
between loci, it is particularly apt for analyzing the multi-
ple loci suggested by GWAS data. By looking at the
GWAS data holistically and incorporating protein infor-
mation, interactions and common features between loci
can be detected, thereby improving candidate disease gene
prediction outcomes. Gentrepid was originally bench-
marked (George et al. 2006) on a standard set of oligo-
genic diseases with Mendelian inheritance from Turner
et al. (2003). It was later benchmarked against other can-
didate gene prediction systems using GWAS data on type
II diabetes from the WTCCC (Wellcome Trust Case Con-
trol Consortium 2007) and DIAGRAM (Zeggini et al.
2007) studies (Teber et al. 2009). More recently, we per-
formed an assessment of the system’s ability to predict
candidate disease genes from GWAS data using several
analysis protocols (Ballouz et al. 2011) and compared the
results to the popular tools GRAIL (Raychaudhuri et al.
2009) and WebGestalt (Duncan et al. 2010).
Here, we demonstrate use of Gentrepid as a discovery
tool to select and prioritize valid disease candidates from
the CAD WTCCC GWAS (Wellcome Trust Case Control
Consortium 2007). Compared to the Framingham study
(de las Fuentes et al. 2012) and other meta-analyses, a
number of interesting novel genes are identified, some in
previously associated loci, which may be valuable to pur-
sue in further genetic and biochemical analyses.
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Materials and Methods
Data sourcing
For the genotype data, we obtained SNP association sum-
mary statistics from the WTCCC (Wellcome Trust Case
Control Consortium 2007) case–control studies of CAD.
We mapped these SNPs to 489,763 autosomal SNPs on
the genome assembly (build 36.3), of which 459,231 SNPs
were retained following WTCCC quality control (Well-
come Trust Case Control Consortium 2007). For geno-
type–phenotype relationship data, we extracted known
CAD disease genes and loci from the Online Mendelian
Inheritance in Man (OMIM) database (Hamosh et al.
2002). We queried the Morbid Map flat file by perform-
ing a text search for the disease name or parts thereof:
“Coronary artery disease”, “coronary heart disease”, and
“coronary”. The results were then manually filtered,
removing duplicate loci and merging adjacent loci. The
final list of known loci consisted of 19 cytogenetic bands
and 13 genes (Fig. 1).
Data preprocessing
We selected four SNP sets by iteratively lowering the
stringency threshold of the Cochran-Armitage P-value of
statistical significance for an association from the original
threshold used in the study. These were a highly signifi-
cant SNP set (HS, PGWA <5 9 10
7), a moderately high
significant set (MHS, PGWA ≤105), a moderately weak
significant set (MWS, PGWA ≤104), and a weakly signifi-
cant set (WS, PGWA ≤103). SNPs in close proximity
(within 50 Kbp) were merged into a single locus.
For each of the four significant SNP sets, we created
six gene search spaces, three based on SNP gene proxim-
ity, labeled the “nearest neighbor” (NN) approach (adja-
cent, nearest, and resident sets), and three based on SNP
gene distance labeled the “bystander” (BY) approach
(1 Mbp, 0.5 Mbp, and 0.1 Mbp sets). For the NN
approach, the resident set includes only genes with signif-
icant SNPs within the gene boundary. The nearest set
contains the closest gene to each SNP. In the adjacent set,
a gene is selected upstream and downstream of each SNP
on both strands of DNA, resulting mostly in four genes
for each SNP. For the BY approach, genes were pooled
from an interval around each SNP of window sizes of
1 Mbp, 0.5 Mbp, and 0.1 Mbp, respectively. As most
SNPs on the chip used by the WTCCC are in noncoding
regions, creating several different search spaces ensured
that likely genes were included in the analysis. The meth-
ods are fully described in the protocol development paper
(Ballouz et al. 2011) and a workflow diagram is provided
(Fig. S1).
Gentrepid data analysis and validation
We analyzed the data with the Gentrepid system, via an
in-house database and local standard database queries
written in structured query language. We used two modes
of input: one that utilizes known disease gene information
as seeds (seeded); and one that uses only genes within the
search space (ab initio). For seeded mode, we used 13
genes already associated with the disease listed in OMIM
(Table 1). We used the original three modules employed
by the system to predict and prioritize candidates: two
systems biology methods, common pathway scanning
(CPS), a pathway-based approach and PPI, a PPI method;
and common module profiling (CMP), a domain-based
homology approach. The systems biology methods are
based on the assumption that common phenotypes are
likely to be associated with proteins that partake in the
same complex or pathway (Badano and Katsanis 2002; Goh
et al. 2007). CMP is a technique based on the principle
that candidate genes have similar functions to disease genes
already determined for the phenotype (Jimenez-Sanchez
et al. 2001). These methods are described in detail in previ-
ous work (George et al. 2006; Ballouz et al. 2011).
We also developed and tested two novel modules that
search for genes that are targeted by common regulatory
factors. These modules are based on the finding that dis-
ruption of regulatory elements in the genome that control
gene expression levels can cause human diseases (Kleinjan
and Coutinho 2009). Disruptions in these elements (cis-
ruptions) could likely affect known disease genes, or novel
genes with similar regulatory elements. As in the CPS
module, significance of both the regulatory elements and
the miRNA target genes are calculated through the stan-
dard one-tailed Fishers test and a P-value is assigned to
each gene for prioritization.
The first of these modules, common regulatory targets
(CRT), searches for genes in the implicated loci that bind
transcription factors. Regulatory information was sourced
from oRegAnno (Griffith et al. 2008), an experimentally
derived and computationally predicted set of regulatory
data. In seeded mode, we searched for common transcrip-
tion factors that bind the regulatory elements of both the
search genes and the known disease genes used as seeds.
For the ab initio approach, CRT searches for enrichment
of genes with common regulation among the loci in the
gene search space.
A second regulatory module (MIR) looks for genes
among the implicated loci that are common miRNA tar-
gets and in regulatory hubs. Dysfunction of miRNAs is
believed to play a role in diseases of the heart, central
nervous system, and immune system (Meola et al. 2009).
MicroRNAs bind to mRNA, inhibiting protein synthesis
through repression of translation or degradation of
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mRNA. Mutations in miRNAs or miRNA target sites pre-
vent proper target recognition, leading to gene dysregula-
tion. MicroRNA data were gathered from mirBase
(Griffiths-Jones et al. 2008), a central online repository
for miRNA nomenclature, sequence data, annotation, and
target prediction. In seeded mode, MIR first searches for
miRNAs that target the known disease genes. The remain-
ing gene targets of these miRNAs are obtained from the
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Figure 1. Candidate disease gene prediction and prioritization heatmap for coronary artery disease (CAD) across the combined gene search spaces.
Panels on the left are seeded predictions made with known disease gene properties. Panels on the right are ab initio predictions. Prediction modules
used for each panel are annotated on the left, from CPS on the top, followed by CMP, PPI, CRT, and MIR, to the combined predictions shown on the
bottom panel. Within each of the 12 panels, the autosomes run along the x-axis, from 1 (left) to 22 (right), and the six gene search spaces
investigated run along the y-axis (annotated on the right), each sub divided from HS (top of wedge) to WS (bottom of wedge). The gene ranking key
is shown on the bottom left. The lightest colors represent highly prioritized genes, while black signifies no prediction or rank. Below the gene
predictions, the original GWAS SNP loci, colored by significance (key on bottom left), are compared to the OMIM loci (blue).
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database and searched for within the gene search space.
In ab initio mode, this method searches for enriched miR-
NAs and returns the gene targets.
We then assessed Gentrepid predictions using the five
modules on the GWAS-implicated loci relative to two val-
idation sets (Table 1). The first set was the 13 OMIM
known disease genes (known validation set). The second
set was the five genes determined as candidates by the
WTCCC study (WTCCC validation set). Finally, we stud-
ied novel predictions made by the Gentrepid modules and
compared these to other GWAS and the current litera-
ture, where available.
Results and Discussion
CAD is a chronic degenerative condition of the coronary
arteries involving the build-up of atherosclerotic plaques,
and a clinical presentation of myocardial infarction. CAD
patients recruited by the WTCCC study had a validated
history of either myocardial infarctions or coronary artery
bypass surgery prior to the age of 66 years (Wellcome
Trust Case Control Consortium 2007). For our analysis,
we collated a set of 13 known CAD disease genes
(Table 1) from OMIM. These relate to metabolism, trans-
port, and signaling of low-density lipoproteins (LDL).
The original data from the WTCCC had one highly
significant locus and six moderately associated loci. For
the least significant SNP association level generated (WS),
the data had 410 implicated loci, with ~49% overlap with
previously implicated regions from OMIM (Fig. 1). For
each of the four SNP sets created (HS, MHS, MWS, and
WS), six gene search spaces were generated (resident,
nearest, adjacent, 0.1 Mbp, 0.5 Mbp, and 1 Mbp), total-
ling 24 search space sets. The largest gene search space
was 2317 annotated genes (WS, 1 Mbp).
The number of predictions made by Gentrepid varied
by search space, and was at most 525 genes for the WS
1 Mbp search space (Fig. 2). Breaking this down by mod-
ule, Gentrepid CPS predicted up to 208 genes in seeded
mode; and up to 292 genes in ab initio mode. CMP seeded
predicted up to 18 genes and CMP ab initio mode pre-
dicted 197 genes. For PPI seeded, up to 39 genes interacted
with the known seed genes, with 19 genes passing the sig-
nificance test. PPI ab initio had over 1000 interacting
genes with 32 genes passing the significance test. The reg-
ulatory modules had very few predictions; CRT seeded
produced one gene prediction, MIR seeded predicted at
most one candidate, while MIR ab initio generated at most
five predictions. The top predictions are listed in Table 2
and the full list of significant predictions is in Table S1.
Table 1. Coronary artery disease validation sets.
Gene accession
(OMIM)
Genes names
(HGNC)
Gene IDs
(Entrez)
Search space set Significance level
1 Mbp 0.5 Mbp 0.1 Mbp A N R HS MHS MWS WS
OMIM
601470 CX3CR1 1524 X X X X X
147545 IRS1 3667 X X X X
152200 LPA 4018 X X X
603507 LRP6 4040 X X
163729 NOS3 4846 X X X
173510 CD36 948 X X X X X
600046 ABCA1 19
600660 MEF2A 4205
158105 CCL2 6347
604824 KL 9365
168820 PON1 5444
602447 PON2 5445
185250 MMP3 4314
WTCCC
605009 ADAMTS7 11173 X X X X X X X X
600160 CDKN2A 1029 X X X X X X X
600431 CDKN2B 1030 X X X X X X X X X
156540 MTAP 4507 X X X X X X X
611427 MTHFD1L 25902 X X X X X X X X X
The search space sets refer to the gene sets created by the different SNP-to-gene methods explained in the text: 1 Mbp, 1 Mbp interval set;
0.5 Mbp, 0.5 Mbp interval set; 0.1 Mbp, 0.1 Mbp interval set; A, adjacent set; N, nearest set; R, resident set. The significance levels refer to the
SNP stringency thresholds used: HS, highly significant; MHS, moderately high significant; MWS, moderately weak significant; WS, weakly signifi-
cant. OMIM genes are the genes from the Online Mendelian Inheritance in Man database. WTCCC are the candidates from the Wellcome Trust
Case Control Consortium study.
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Candidate predictions in previously
implicated loci
Our first assessment of the Gentrepid predictions tested
its ability to predict known disease genes and the disease
gene candidates from previous studies. We looked for the
predictions and ranks of known disease genes implicated
in CAD from the OMIM database, and for the candidate
disease genes implicated by the WTCCC study (Table 1).
Of the 13 OMIM disease genes implicated in CAD, up
to six were in at least one of the CAD gene search spaces
constructed from the WTCCC SNPs and seven were out-
side the search spaces and discarded from the validation
process. Four of these were detected by CPS from path-
ways using the seeded or ab initio method. Three of these
genes were supported by multiple SNPs in the GWAS
data. These were chemokine (C-X3-C motif) receptor 1
CX3CR1 (MIM 601470) in 3p22.1-3, a chemokine
involved in LDL signaling pathways; and CD36 (MIM
173510) and insulin receptor substrate 1 IRS1 (MIM
147545), which are both receptors in the adipocytokine
signaling pathway. A fourth gene, nitric oxide synthase 3,
NOS3 (MIM 163729) in 7q21.11, though only supported
by SNPs in the WS set, was predicted through CPS
seeded. Lipoprotein A (LPA, 6q27, MIM 152200), also
only supported by weak SNP association signals, was pre-
dicted through CMP (Table 2).
Of the five reported WTCCC genes of interest, all five
genes were predicted by Gentrepid by either CPS or CMP
(Table 2) and were highly ranked. Cyclin-dependent kin-
ases inhibitors CDKN2A/B (MIM 600160/MIM 600431)
and a phosphorylase MTAP (MIM 156540), associated
with a single highly significant locus (9p21), were pre-
dicted via common metabolic pathways along with a
modestly associated dehydrogenase MTHFD1L (6q25,
MIM 611427). The metalloproteinase ADAMTS7 (MIM
605009), implicated by a modest association (15q24), had
common domains with another metalloproteinase in the
gene search spaces.
Novel candidate disease gene predictions
Our next assessment was to analyze the candidate disease
gene predictions that had not been previously reported at
the time of the generation of the data. First, we looked at
the candidates predicted in loci that were previously
implicated but had no known or candidate disease gene,
as not all the loci listed in OMIM have candidates. Of 15
previously determined disease loci, all contained WS
SNPs. Only five loci contained MWS SNPs and one locus
contained MHS SNPs. None of the previously implicated
loci were detected at the HS level. The largest numbers of
SNPs were associated with 2q36.3 and 3p22-p21 in which
CX3CR1 (MIM 601470) and IRS1 (MIM 147545) have
previously been identified as the disease genes. Predictions
within previously determined loci for which a known
gene has not been determined were based on very weak
genetic signals, typically one, or at most two WS SNPs.
Figure 2. Number of significant predictions for CAD. The data are split across SNP/gene sets and are represented on a log10 scale. As per the
key, the total predictions are shown by the purple bar, seeded mode predictions are the shapes in light grey with black border, ab initio
predictions in white with black border. CMP predictions as triangles, CPS predictions as diamonds, PPI predictions as horizontal bars, CRT
predictions as crosses, MIR predictions as circles, and the combined predictions as squares. The WS sets and 1 Mbp mappings had the most
prediction results.
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They include tyrosine kinase 2 TYK2 (MIM 176541) in
19q13, regulatory factor X RFX5 (MIM 601863)
in 1q21.2, fragile histidine triad FHIT (MIM 601153) in
3p14.2, and the tumor necrosis factor receptors
TNFRSF10A-D (MIM 603611, MIM 603612, MIM
603613, MIM 603614) in 8p21.2.
In addition, 15 alternative gene predictions were made
for loci with previously determined disease genes. Of
these, the IjB kinase complex-associated protein IKBKAP
(MIM 603722) in 9q31.2 was recently shown to be differ-
entially regulated in patients with acute myocardial infarc-
tion compared to controls (Dabek et al. 2009). The
disease gene previously implicated for this region is the
ATP-binding cassette ABCA1 (MIM 600046).
Common pathway candidates
We then looked at the novel candidates from each of the
modules for the regions implicated by our novel methodol-
ogy and SNP/gene mappings. Two of the most significant
pathways predicted by Gentrepid CPS in loci novel to the
WTCCC study were diabetes related. In the “Type II diabe-
tes mellitus” pathway (MWS set, Ppath,adjacent = 0.005),
three genes in three novel loci (10q23, 13q34, 20p11) were
implicated in addition to the known disease gene IRS1
(MIM 147545). In the MWS set, the “Insulin signaling
pathway” was the most significant (Ppath,nearest = 0.0003).
Patients with T2D are known to have a higher risk of
CAD. The possible commonality of pathways underlying
CAD and T2D was raised by Torkamani et al. (2008) based
on their analysis of the WTCCC data. In addition two
hypoxia-related pathways suggested hypoxia-inducible fac-
tor HIF1A (MIM 603348) as a candidate. Overall, 56 novel
pathways were predicted in ab initio mode across all the
gene search spaces (Table S2).
We also wished to compare our pathway results to pre-
dictions from the Framingham study (de las Fuentes et al.
2012) which used variable set enrichment analysis (VSEA)
to uncover significant pathways. Of the 25 pathways they
found to be significant, the “Rac 1 cell motility signaling
pathway” was the only significant pathway in both our
studies. Of the 18 genes predicted by this pathway in the
Framingham study, CPS ab initio and seeded module
(Table S1) predicted three of those genes: RAC1 (Ras-
related C3 botulinum toxin substrate 1, MIM 602048),
PDGFRA (Alpha-type platelet-derived growth factor
receptor, MIM 173490), and PLD1 (phospholipase D1,
phosphatidylcholine-specific, MIM 602382) (PWS,adja-
cent = 0.007). WASF1 (Wiskott-Aldrich syndrome protein
family member 1, MIM 605035), and the enzyme LIM
domain kinase (LIMK1, MIM 601329,
PWS,0.5 Mbp = 0.018) were not in the Framingham study
but were predicted by our method. LIMK1 (MIMTa
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601329) may be involved in cardiovascular disease
through its interactions with BMP type II receptor
(BMPR2, MIM 600799) (Scott and Olson 2007).
Domain homology candidates
Protein domains are highly conserved globular structures
each with their own biochemical function (Finn et al.
2008). In combination, domains can be used to assign a
function to a protein and its gene (Patthy 2003). Thus
using domain homology, genes with unknown functions
can potentially be identified as candidates. Gentrepid
CMP seeded found five genes with similarities to LDL
receptor-like protein LRP6 (MIM 603507) in the gene
search spaces; two genes homologous to the lipoprotein
carrier LPA (MIM 152200): PLG (MIM 173350) and
LPAL2 (MIM 611682); and a matrix metalloproteinase
(MMP15, MIM 602261) similar to MMP3 (MIM 185250),
involved in extracellular matrix (ECM) breakdown (Table
S3). Many plausible candidates were predicted by CMP
ab initio (Table S4). Cell–cell and ECM adhesion, as well
as their remodeling, featured prominently. Genes with the
strongest genetic support are the vascular adhesion factors
SEZ6L (22q11.23, MIM 607021) and CSMD2 (1p35.1,
MIM 608398). Adhesion between the cell and the ECM is
implicated by multiple integrins and matrix metallopro-
teases as well as by transforming growth factor TGFBI
(MIM 601692) and periostin POSTN (MIM 608777).
TGFBI (MIM 601692) binds to type I, II, and IV colla-
gens. Other adhesion genes predicted were adhesion
G-protein coupled receptors. Lipid signaling was also
implicated by phospholipases, DAG kinases, and protein
kinase C-like genes (Table S4).
Predictions from the PPI module
For the PPI module, where the search was limited to
direct interaction partners, the sets with more genes (1
and 0.5 Mbp) and less stringent significant thresholds
(WS and MWS) had the greatest number of predictions
in both seeded and ab initio modes. Some of the predic-
tions were the same as those from the CPS and CMP
modules, such as the chemokine receptors CCR1, 2, 3,
and 5 (MIM 601159, MIM 601267, MIM 601268, and
MIM 601373) that interact with known disease gene
CCL2 (MIM 158105), and LIMK1 (MIM 601329) that
interacts with ABCA1 (MIM 600046) (Fig. 3 and Table
S5).
The significant predictions of the PPI ab initio module
are listed in Tables S6, S7. Visualizations of the interac-
tions (Fig. 4) implicate protein interaction hubs such
as the ubiquitin-conjugating enzyme UBE2G2 (MIM
603124) or the ubiquitin-specific processing protease
USP7 (MIM 602519). The ubiquitin–proteasome complex
and proper protein degradation are involved in cardiovas-
cular physiology and disease with roles in endothelial
function and atherosclerosis (Depre et al. 2010).
Predictions from regulatory modules
Very few predictions were returned for the Gentrepid reg-
ulatory modules MIR and CRT. For CRT, the known
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Figure 3. CAD PPI seeded interactions. The genes in magenta are the known OMIM seed genes used for the PPI module. The lines represent an
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IRS1 (MIM 147545) gene was the sole prediction. For the
MIR module, IRS1 (MIM 147545) was the only signifi-
cant prediction in seeded mode. The miRNAs that impli-
cated this gene were mir-126, known to be involved in
angiogenesis (Van Solingen et al. 2009) and mir-145,
involved in vascular smooth muscle differentiation (Cordes
et al. 2009) and possibly CAD (Fichtlscherer et al. 2010).
In ab initio mode, several genes were predicted from
the WS sets which were all implicated by the family of
miRNAs from the mir-181 precursor (Table S8). The
homeobox CDX2 (MIM 600297), transcription factor
GATA6 (MIM 601656) and axin interactor AIDA (MIM
612375) are regulated by the mir-181 family. Mir-181 tar-
get genes are involved in myogenesis, muscle regeneration
(Naguibneva et al. 2006), and hematopoiesis (Chen et al.
2004). GATA6 (MIM 601656) mutations are known to
cause congenital heart defects (Maitra et al. 2009). Thus
risk alleles of this transcription factor could plausibly con-
tribute to CAD. AIDA (MIM 612375) is highly expressed
in the heart and skeletal muscle, also making it an
interesting candidate (Rui et al. 2007). Predictions of a
read-through transcript TGIF2-C20orf24 and DNA meth-
yltransferase DNMT1 (MIM 126375) by their common
regulator mir-148 are interesting predictions, as mir-148a
also promotes skeletal muscle differentiation (Zhang et al.
2012).
Further case study: CAD meta-analyses
A recent meta-analysis GWA on CAD called the CARDIo-
GRAMplusC4D study (Deloukas et al. 2012) discovered
15 novel association loci and listed 20 likely candidate
genes. We again wished to compare our method to this
study’s results. First, we checked if their significant loci
were a subset of the less significant loci from the WTCCC
and found very few overlaps. Whether these overlaps are
simply due to chance or a significant association that was
missed in the stringent threshold is hard to determine.
Nonetheless, we still wished to see if our method was
capable of selecting appropriate candidates from this new
set of loci. We then took the novel loci, mapped them to
their adjacent genes and ran Gentrepid, comparing their
candidates with our predictions. Of the 20 genes that
were selected as candidates from the CARDIoGRAMp-
lusC4D study, 16 genes were mapped by our adjacent
SNP-to-gene mapping, and Gentrepid predicts and priori-
ELAVL2
KLHDC10
C1QBP
NCBP1
STRBP
UBE2G2
CNOT1
CS
HLCSUBE2H
ALG11
SETD6
RNF157
XPR1
SRP68
EXOC5
STX1A
CCDC90A
POLH
POLR1C
GUF1
PRIM1
ALDH18A1
MRPL38
USP7
CDK3
GTF2I
PCSK9
RPSA
CCNE1
KIF11
ATP5BGNAI3
IDH3A
ABHD11
MORF4L1
SKP2
H3F3B
CHD1
CHAF1B
ZFPM2UQCRFS1
BTAF1
NFKBI E
PAAF1
AADAT
PSMA5
PSMA4 GINS3 GINS1
TAF13
SMARCC2
AQP4
CSNK2A2
SUMO3
KALRN
RANBP9
ITGB2
ENTPD1
HSP90AB1
ENTPD6
CLPX
IRS1
CDKN2A
MAP1LC3B
SLC38A7
RABGAP1
RAB6A
NANS
ELAC2
WDR48
ECHDC3
PTPLAD1
MTHFD1L
NACA
CDK2
GOT2
XPA
SORT1
CDC5L
GPSM2
ESYT1
SARS
ZBTB2
PMM2
RFC2
INTS6
TP53BP2
TPST2CCR8
WBP2WWOX
RECQL5MED10
CLASP1CLIP2
MRRFEXOC7
ITGB5P2RY2
USP7 GTF2I
CLIP2 CLASP1
MWSMHS
Resident 
Nearest
Adjacent
0.1Mbp
0.5Mbp
1Mbp
SNP/gene set
Known
Candidate
Figure 4. CAD PPI ab initio interactions for the MHS and MWS sets. The genes in magenta are the known OMIM seed genes used for the PPI
module. The lines represent an interaction. The different colors represent the gene search space the interaction arises from. Resident set
interactions in blue, nearest set in red, adjacent set in green, 0.1 Mbp set in yellow, 0.5 Mbp set in orange, and 1 Mbp set in purple.
ª 2013 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. 53
S. Ballouz et al. Candidate Genes for Coronary Artery Disease
tizes 11 of these genes (Table 3 and Table S9). Gentrepid
also made three alternate predictions: the leucine-rich
PPR motif-containing protein, mitochondrial gene
(LRPPRC, MIM 607544), mitogen-activated protein
kinase kinase kinase 4 (MAP3K4, MIM 602425) and gua-
nylate cyclase soluble subunit beta-1 (GUCY1B3, MIM
139397). GUCY1B3 (MIM 139397) is known to interact
with the endothelial NOS (NOS3, MIM 163729), a gene
associated with ischemic heart disease and hypertension
(Casas et al. 2004). Our analyses once again showed that
the system was capable of making valid predictions based
on biological knowledge, and also generate novel hypoth-
eses based on enrichment of common pathways and func-
tional domains within the data.
Caveats
Although we aimed to predict and prioritize a list of can-
didate disease genes, there still remains a reasonably high
probability (50/50 at worst) that a result is a false posi-
tive. From our methods paper (Ballouz et al. 2011), we
calculated the specificity of the system to be between 0.55
and 1, depending on the method used. Further to this,
even the list of candidates used to validate our study
may also be false positives, and therefore skew our calcu-
lations. For instance, the 6q25 locus was not replicated in
other studies (Kathiresan et al. 2009) and therefore the
MTHFD1L (MIM 611427) gene may be a false-positive
result. However, the OMIM validation set contained
genes that were selected by our system, thereby validating
the technique to some extent. Also, by demonstrating
that Gentrepid selected at least half of the candidates
from the CARDIoGRAMplusC4D, the system appears
competitive with meta-analysis methods used by
researchers to determine candidates. The system also
made alternate predictions which might be of interest
too. Another point to note is the low concordance of the
pathway enrichment results with the Framingham study
(de las Fuentes et al. 2012). A few reasons for this
include the fact that we used different gene data sets as
input to which the methods are highly sensitive to (Glaab
et al. 2012). A very highly annotated gene in one set yet
missing in the other will skew results depending how the
significance is calculated. Although it would have been
reassuring to have obtained a larger overlap in the path-
ways, it nonetheless brings to light how dependent the
methods, in particular gene set enrichment, are on the
underlying data.
Table 3. CAD predictions made by Gentrepid for the CARDIoGRAMplusC4D loci.
Gene accession
(OMIM) Gene (HGNC)
CARDIoGRAMplusC4D
SNP Method Common biological support Score Rank
190030 FES rs17514846 CMP-ab Pkinase_tyr ○ 2
165070 FLT1 rs9319428 CMP-ab Pkinase_tyr ○ 2
193002 SLC18A1 rs264 CMP-ab MFS_1 ○ 1
604190 SLC22A4 rs273909 CMP-ab MFS_1 ○ 1
131243 EDNRA rs1878406 CMP-s 7tm_1 ● 3
173350 PLG rs4252120 CMP-s Kringle ●●●● 1
605460 ABCG8 rs6544713 CMP-s ABC_tran ● 2
147880 IL6R rs4845625 CPS-ab IL 6 signaling pathway|
Role of ERBB2 in signal transduction
and oncology
◊◊◊ 1
607544 LRPPRC rs6544713 CPS-ab IL 6 signaling pathway|
Role of ERBB2 in signal transduction
and oncology
◊◊◊ 1
605459 ABCG5 rs6544713 CPS-s Nuclear receptors in lipid metabolism
and toxicity
* 2
139396 GUCY1A3 rs7692387 CPS-s Long-term depression * 6
139397 GUCY1B3 rs7692387 CPS-s Long-term depression * 6
609708 LPL rs264 CPS-s Low-density lipoprotein (LDL) pathway
during atherogenesis
◊◊ 1
602425 MAP3K4 rs4252120 CPS-s MAPKinase Signaling Pathway * 8
Method: ab, ab initio; s, seeded. Common biological support column depends on method. For CMP-s, common gene and common domain are
listed. For CMP-ab, only the common domain. For CPS-s and CPS-ab, the common pathway is listed. For PPI-s, the HGNC gene name of the gene
(s) are listed. For MIR-s, the common miRNA ID is listed. For CRT, the common oRegAnno ID is listed. Gentrepid scoring: CMP-ab: ○○○○○, log
v2 ≥ 2.5; ○○○○, 2 ≤ log v2 < 2.5; ○○○, 1.5 ≤ log v2 < 2; ○○, 1 ≤ log v2 < 1.5; ○, log v2 < 1. CMP-s: ●●●●, Sc > 0.7; ●●●, Sc > 0.6; ●●,
Sc > 0.5; ●, Sc > 0.4. Other: ◊◊◊◊, P < 0.005; ◊◊◊, P < 0.01; ◊◊, P < 0.025; ◊, P < 0.05; *, not significant. Rank represents ranking score in prior-
itization of gene in module, not overall ranking. Genes in bold are candidate predictions not selected by the CARDIoGRAMplusC4D.
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Conclusions
We performed an extensive analysis of the GWAS data
for CAD. The approach used four sets of significant SNPs
filtered at different significance thresholds. Gene search
spaces were generated in six different ways and the result-
ing sets analyzed with the Gentrepid candidate gene pre-
diction system. The results show that using a less
stringent significance threshold increases the noise in the
system, yet even so brings out likely candidate disease
genes. Looking beyond the nearest gene in order to find
suitable disease candidates, in both the adjacent and BY
approaches, is also valuable for the analysis of GWAS
data, in particular for the gene desert regions with regula-
tory elements.
Which method is best?
Biological filtering improves the amount of knowledge
extracted from the study. Using the blind method (ab ini-
tio), no prior disease gene information is required, allow-
ing for the discovery of novel pathways and regulatory
elements that may be important in the disease that were
not previously considered, along with protein domains
attributing novel functions to the mechanisms behind the
disease. The few functionally annotated miRNAs that pro-
duced predictions had relevant biological functionality in
the phenotype and it would be very interesting to prod
further into these, in particular genes GATA6 (MIM
601656) and AIDA (MIM 612375). MicroRNA research is
expanding and will produce motivating hypotheses rele-
vant to disease. Further to this, genes such as RAC1
(MIM 602048), LIMK1 (MIM 601329), SEZ6L (MIM
607021), and CSMD2 (MIM 608398) also warrant further
investigation as they were predicted by multiple methods
or had strong genetic support.
Generally, we recommend the use of the adjacent gene
method or genes within a 0.1–0.5 Mbp interval to create
the search space sets. Most systems use biological path-
ways and GO terms to predict disease gene candidacy
(Tranchevent et al. 2011), therefore the use of CMP
would be recommended as it is unique to Gentrepid.
Although there are alternate methods that capitalize on
gene and pathway enrichment analysis (Raychaudhuri
et al. 2009; Duncan et al. 2010; de las Fuentes et al.
2012) and PPI data (Jensen et al. 2011), our method
incorporates multiple methods along with functional pro-
tein domain information. The Gentrepid webserver is
available for free usage by educational and nonprofit
research institutes (https://www.gentrepid.org). Registra-
tion is free and data are stored remotely and securely.
Each of the methods highlighted here can be performed
with the exception of the regulatory modules CRT and
MIR under development. The only input required is a list
of SNPs or markers and an optional phenotype for the
seeded mode.
As in all candidate disease gene methods, it is still diffi-
cult to perform a fair assessment of the results without
further biochemical functional studies. Overall, we believe
our pipeline is a suitable methodology for generating
plausible hypotheses from GWAS. The study demon-
strates that using existing knowledge and a holistic multi-
ple loci approach provides insight into what is a very
complex disease.
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